Asset profile
ALZ-101
Vaccine
Evidence outlook · lead readout
NCT05328115 · Alzheimer Disease, Dementia Alzheimers, Dementia, Mild
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05328115: Most of the trial was randomized and blinded against placebo, but the highest-dose group was given openly rather than blinded, and only 33 people took part. No results have been posted yet, so there is nothing to confirm the drug worked.
Reports Part A of the trial (26 randomised participants), fewer than the trial's registered enrollment of 33.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.